Form 4: Director Sarah Teichmann Receives 10x Genomics RSU Grant

Director Sarah Teichmann was granted 8,829 restricted stock units in 10x Genomics, Inc. as part of standard equity compensation.

Summary

• Director Sarah A. Teichmann acquired 8,829 restricted stock units (RSUs) of 10x Genomics, Inc. (TXG) on June 4, 2026.
• Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting.
• The RSUs vest in equal quarterly installments over one year, beginning May 21, 2026, contingent upon continued service.
• Following this transaction, the reporting person holds a total of 35,609 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation.

Positives

• The grant aligns the director's interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified; this is a standard compensatory equity grant.

Risks

• Vesting is subject to the reporting person continuing as a service provider to the company.

Future Outlook

The RSUs will vest in four equal quarterly installments starting from May 21, 2026, provided the director remains a service provider.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology and life sciences sector to ensure board alignment with company performance.

Comparison to Industry Standards

• The grant structure is consistent with standard equity compensation packages for board members in the life sciences industry.
• Vesting schedules of one year for director equity are common among mid-to-large cap biotech firms.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine equity grant to a director.

Next Steps

• Quarterly vesting of the granted RSUs beginning after May 21, 2026.

Key Dates

Keywords

10x Genomics, TXG, Form 4, Insider Transaction, Restricted Stock Units, Equity Compensation